

Name of the Issuer:		Krsnaa Diagnostics Limited	Last updated on		15-Nov-23																									
1	Type of Issue (IPO / FPO)		IPO																											
2	Issue Size (Rs. Cr)		1213.3																											
	- Fresh Issue Size (Rs. Cr)		400.0																											
	- Offer for Sale Component (Rs. Cr)		813.3																											
	Source: Post Issue Monitoring Report																													
3	Grade of issue along with name of the rating agency																													
	Name	Not Applicable																												
	Grade	Not Applicable																												
4	Subscription Level (Number of times)		36.05*																											
	Source: Post Issue Monitoring Report																													
	*The above figure is after technical rejections and includes anchor																													
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges																													
	<table><tr><th>Particulars</th><th>%</th></tr><tr><td>(i) allotment in the issue <sup>(1)</sup></td><td>30.08%</td></tr><tr><td>(ii) at the end of the 1st Quarter immediately after the listing of the issue</td><td>36.16%</td></tr><tr><td>(iii) at the end of 1st FY (March 31, 2022)</td><td>33.13%</td></tr><tr><td>(iv) at the end of 2nd FY (March 31, 2023)*</td><td>21.87%</td></tr><tr><td>(v) at the end of 3rd FY (March 31, 2024)*</td><td>Not Available</td></tr></table>					Particulars	%	(i) allotment in the issue <sup>(1)</sup>	30.08%	(ii) at the end of the 1st Quarter immediately after the listing of the issue	36.16%	(iii) at the end of 1st FY (March 31, 2022)	33.13%	(iv) at the end of 2nd FY (March 31, 2023)*	21.87%	(v) at the end of 3rd FY (March 31, 2024)*	Not Available													
Particulars	%																													
(i) allotment in the issue <sup>(1)</sup>	30.08%																													
(ii) at the end of the 1st Quarter immediately after the listing of the issue	36.16%																													
(iii) at the end of 1st FY (March 31, 2022)	33.13%																													
(iv) at the end of 2nd FY (March 31, 2023)*	21.87%																													
(v) at the end of 3rd FY (March 31, 2024)*	Not Available																													
	* QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.																													
	(1) Source: Minutes of Basis of Allotment. Includes allotment to Anchor Investors																													
	# Source: Reporting with the BSE. Represents holding of Institutions category																													
6	Financials of the issuer																													
	(In Rs. Crore)																													
	<table><tr><th>Parameters (consolidated)</th><th>1st FY (March 31, 2022)</th><th>2nd FY (March 31, 2023)</th><th>3rd FY (March 31, 2024)*</th></tr><tr><td>Income from operations</td><td>455.45</td><td>487.123</td><td>Not Available</td></tr><tr><td>Net Profit for the period</td><td>68.39</td><td>62.11</td><td>Not Available</td></tr><tr><td>Paid-up equity share capital</td><td>15.70</td><td>15.70</td><td>Not Available</td></tr><tr><td>Reserves excluding revaluation reserves</td><td>668.71</td><td>738.74</td><td>Not Available</td></tr></table>					Parameters (consolidated)	1st FY (March 31, 2022)	2nd FY (March 31, 2023)	3rd FY (March 31, 2024)*	Income from operations	455.45	487.123	Not Available	Net Profit for the period	68.39	62.11	Not Available	Paid-up equity share capital	15.70	15.70	Not Available	Reserves excluding revaluation reserves	668.71	738.74	Not Available					
Parameters (consolidated)	1st FY (March 31, 2022)	2nd FY (March 31, 2023)	3rd FY (March 31, 2024)*																											
Income from operations	455.45	487.123	Not Available																											
Net Profit for the period	68.39	62.11	Not Available																											
Paid-up equity share capital	15.70	15.70	Not Available																											
Reserves excluding revaluation reserves	668.71	738.74	Not Available																											
	* Financials not disclosed as reporting for the relevant fiscal year has not been completed.																													
7	Trading Status in the scrip of the issuer																													
	Company's Equity Shares are listed on both the BSE Limited and the NSE.																													
	The Shares have not been suspended or delisted.																													
	<table><tr><th>Particulars</th><th>Status</th></tr><tr><td>(i) at the end of 1st FY (March 31, 2022)</td><td>Frequently traded</td></tr><tr><td>(ii) at the end of 2nd FY (March 31, 2023)</td><td>Frequently traded</td></tr><tr><td>(iii) at the end of 3rd FY (March 31, 2024)*</td><td>Not Available</td></tr></table>					Particulars	Status	(i) at the end of 1st FY (March 31, 2022)	Frequently traded	(ii) at the end of 2nd FY (March 31, 2023)	Frequently traded	(iii) at the end of 3rd FY (March 31, 2024)*	Not Available																	
Particulars	Status																													
(i) at the end of 1st FY (March 31, 2022)	Frequently traded																													
(ii) at the end of 2nd FY (March 31, 2023)	Frequently traded																													
(iii) at the end of 3rd FY (March 31, 2024)*	Not Available																													
	* Trading status not disclosed as the relevant fiscal year has not been completed.																													
8	Change in Directors of issuer from the disclosures in the offer document																													
	<table><tr><th>Particulars</th><th>Name of the Director</th><th>Appointed / Resigned</th></tr><tr><td>(i) at the end of 1st FY (March 31, 2022)</td><td>-</td><td>-</td></tr><tr><td>(ii) at the end of 2nd FY (March 31, 2023)</td><td>Adesh Kumar Gupta</td><td>Appointed</td></tr><tr><td></td><td>Prakash Iyer</td><td>Resigned</td></tr><tr><td>(iii) at the end of 3rd FY (March 31, 2024)*</td><td>-</td><td>-</td></tr></table>					Particulars	Name of the Director	Appointed / Resigned	(i) at the end of 1st FY (March 31, 2022)	-	-	(ii) at the end of 2nd FY (March 31, 2023)	Adesh Kumar Gupta	Appointed		Prakash Iyer	Resigned	(iii) at the end of 3rd FY (March 31, 2024)*	-	-										
Particulars	Name of the Director	Appointed / Resigned																												
(i) at the end of 1st FY (March 31, 2022)	-	-																												
(ii) at the end of 2nd FY (March 31, 2023)	Adesh Kumar Gupta	Appointed																												
	Prakash Iyer	Resigned																												
(iii) at the end of 3rd FY (March 31, 2024)*	-	-																												
	* Changes in Directors updated till November 15, 2023 as the relevant fiscal year has not been completed.																													
9	Status of implementation of project/ commencement of commercial production																													
	(i) as disclosed in the offer document																													
	(ii) Actual implementation																													
	Not applicable*																													
	(iii) Reasons for delay in implementation, if any																													
	*The Company did not undertake any implementation of project hence the same is not applicable																													
10	Status of utilization of issue proceeds																													
	(i) as disclosed in the offer document																													
	(In Rs. Crore)																													
	<table><tr><th>Particulars</th><th>Total estimated amount/ expenditure</th><th>Estimated utilisation from Net Proceeds</th><th>Estimated Deployment (Financial Year 2022)</th><th>Estimated Deployment (Financial Year 2023)</th></tr><tr><td>Finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra</td><td>150.81</td><td>150.81</td><td>125.00</td><td>25.81</td></tr><tr><td>Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by our Company</td><td>146.08</td><td>146.08</td><td>146.08</td><td>0.00</td></tr><tr><td>General corporate purposes</td><td>81.74</td><td>81.74</td><td>81.74</td><td>0.00</td></tr><tr><td>Total</td><td>378.63</td><td>378.63</td><td>352.82</td><td>25.81</td></tr></table>					Particulars	Total estimated amount/ expenditure	Estimated utilisation from Net Proceeds	Estimated Deployment (Financial Year 2022)	Estimated Deployment (Financial Year 2023)	Finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra	150.81	150.81	125.00	25.81	Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by our Company	146.08	146.08	146.08	0.00	General corporate purposes	81.74	81.74	81.74	0.00	Total	378.63	378.63	352.82	25.81
Particulars	Total estimated amount/ expenditure	Estimated utilisation from Net Proceeds	Estimated Deployment (Financial Year 2022)	Estimated Deployment (Financial Year 2023)																										
Finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra	150.81	150.81	125.00	25.81																										
Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by our Company	146.08	146.08	146.08	0.00																										
General corporate purposes	81.74	81.74	81.74	0.00																										
Total	378.63	378.63	352.82	25.81																										
	(ii) Actual utilization																													
	<table><tr><th>Particulars</th><th>Amount to be deployed from Net Proceeds</th><th>Revised cost</th><th>Amount utilized as at September 30, 2023*</th><th>Amount unutilized as at September 30, 2023*</th></tr><tr><td>Finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra</td><td>150.81</td><td>150.81</td><td>98.70</td><td>52.11</td></tr><tr><td>Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by our Company</td><td>146.08</td><td>146.08</td><td>146.08</td><td>0.00</td></tr><tr><td>General corporate purposes</td><td>81.74</td><td>81.31</td><td>81.31</td><td>0.00</td></tr><tr><td>Total</td><td>378.63</td><td>378.20</td><td>326.09</td><td>52.11</td></tr></table>					Particulars	Amount to be deployed from Net Proceeds	Revised cost	Amount utilized as at September 30, 2023*	Amount unutilized as at September 30, 2023*	Finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra	150.81	150.81	98.70	52.11	Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by our Company	146.08	146.08	146.08	0.00	General corporate purposes	81.74	81.31	81.31	0.00	Total	378.63	378.20	326.09	52.11
Particulars	Amount to be deployed from Net Proceeds	Revised cost	Amount utilized as at September 30, 2023*	Amount unutilized as at September 30, 2023*																										
Finance the cost of establishing diagnostics centres at Punjab, Karnataka, Himachal Pradesh and Maharashtra	150.81	150.81	98.70	52.11																										
Repayment/pre-payment, in full or part, of borrowings from banks and other lenders availed by our Company	146.08	146.08	146.08	0.00																										
General corporate purposes	81.74	81.31	81.31	0.00																										
Total	378.63	378.20	326.09	52.11																										
	*Monitoring agency report dated November 09, 2023																													
	(iii) Reasons for deviation, if any																													
	None																													
11	Comments of monitoring agency, if applicable																													
	<table><tr><td>(a) Comments on use of funds</td><td rowspan="3">No comments*</td></tr><tr><td>(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document</td></tr><tr><td>(c) Any other reservations expressed by the monitoring agency about the end use of funds</td></tr></table>					(a) Comments on use of funds	No comments*	(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	(c) Any other reservations expressed by the monitoring agency about the end use of funds																					
(a) Comments on use of funds	No comments*																													
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document																														
(c) Any other reservations expressed by the monitoring agency about the end use of funds																														
	*Monitoring agency report date August 15,2023																													

12 Pricing Data												
Issue Price (Rs.):		954										
Designated Stock Exchange:		NSE										
Listing Date:		16-Aug-21										
Price parameters	At close of listing day (Aug 16, 2021)	At close of 30th calendar day from listing day (Sep 14, 2021) <sup>(1)</sup>	At close of 90th calendar day from listing day (Nov 13, 2021) <sup>(2)</sup>	As at the end of 1st FY after the listing of the issue (March 31, 2022)			As at the end of 2nd FY after the listing of the issue (March 31, 2023) <sup>(3)</sup>			As at the end of 3rd FY after the listing of the issue (March 31, 2024) <sup>(3) (4)</sup>		
				Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange	987.00	864.15	689.45	488.70	1,099.70	480.00	460.20	655.00	353.10	Not Available	Not Available	Not Available
NIFTY 50	16,563.05	17,380.00	18,102.75	17,464.75	18,604.45	15,671.45	17,359.75	18,887.60	15,183.40	Not Available	Not Available	Not Available
Sectoral index <sup>(5)</sup>	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Note:												
(1) 30th calendar day shall be taken as listing date plus 29 calendar days.												
(2) 90th calendar day shall be taken as listing date plus 89 calendar days.												
(3) High and Low based on intra day prices.												
(4) Pricing data not disclosed as the relevant fiscal year has not completed.												
(5) There is no sectoral index												

13 Basis for Issue Price					
Accounting ratio	As disclosed in the offer document <sup>(1)</sup>	At the end of 1st FY (March 31, 2022)	At the end of 2nd FY (March 31, 2023) <sup>(2)</sup>	At the end of 3rd FY (March 31, 2024) <sup>(3)</sup>	
EPS	<b>Issuer:</b>				
	Basic	71.86	22.89	19.78	Not Available
	<b>Peer Group:</b>				
	Metropolis Healthcare Limited (Basic)	35.97	41.87	27.14	Not Available
	Dr. Lal Pathlabs Limited (Basic)	35.33	41.70	26.62	Not Available
	<b>Industry Avg:</b>	Not Applicable	Not Applicable	Not Applicable	Not Applicable
P/E	<b>Issuer:</b>				
	Basic	77.88	21.35	23.27	Not Available
	<b>Peer Group:</b>				
	Metropolis Healthcare Limited (Basic)	77.65	48.64	46.02	Not Available
	Dr. Lal Pathlabs Limited (Basic)	94.32	62.52	68.67	Not Available
	<b>Industry Avg:</b>	85.99	55.58	57.34	Not Available
RoNW (%)	<b>Issuer:</b>	79.76%	9.99	8.41	Not Available
	<b>Peer Group:</b>				
	Metropolis Healthcare Limited	25.91	24.17	15.32	Not Available
	Dr. Lal Pathlabs Limited	23.42	22.78	14.19	Not Available
	<b>Industry Avg:</b>	Not Applicable	Not Applicable	Not Applicable	Not Applicable
NAV per share	<b>Issuer:</b>	85.27	217.98	235.28	Not Available
	<b>Peer Group:</b>				
	Metropolis Healthcare Limited	138.23	173.18	182.78	Not Available
	Dr. Lal Pathlabs Limited	149.39	180.93	203.86	Not Available
	<b>Industry Avg:</b>	Not Applicable	Not Applicable	Not Applicable	Not Applicable
<b>Notes:</b> (1) Sourced from Prospectus. (2) Information sourced from financials filed by the Issuer Company and Peers on the stock exchanges (3) Information not provided as the relevant fiscal year has not completed Key ratios for the Company for 1st FY and 2nd FY stated above are calculated as follows: (i) Basic and diluted earnings per Equity Share are based on the Annual Reports for the relevant years (ii) P/E - Closing Market Price on BSE as of relevant fiscal year / EPS (diluted); Also disclosed EPS (basic) for the Issuer (iii) RoNW - Net profit after tax attributable to the owners divided by net worth at the end of the relevant period (iv) NAV per share - Net worth at the end of the relevant period divided by Total Equity Shares Outstanding as of fiscal year end					

14 Any other material information	
Date of disclosure to Designated Stock Exchange	Announcement
26-Aug-21	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with Government of Punjab ("Agreement") for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company will be inaugurating its first Diagnostics Center of the above mentioned Agreement at Mohali, Punjab on August 31, 2021 which will provide CT Scan, MRI & Pathology Laboratory facilities.
30-Sep-21	Krснаа Diagnostics Lidhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/10/2021, inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of the SEBI (LODR) Regulations, 2015 and all other applicable provisions in this behalf, we wish to inform you that the Meeting of the Board of Directors of Krснаа Diagnostics Limited ("the Company") is scheduled to be held on Monday, 11th October, 2021, through audio-visual means, inter alia, to consider and approve Unaudited (Standalone and Consolidated) Financial Results ("UFR"), for the quarter and six months ending on 30th September, 2021 and to take on record, the Limited Review Report thereon
6-Oct-21	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 submitted
7-Oct-21	Statement Of Investor Complaints For The Quarter Ended September 2021 submitted
11-Oct-21	Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended on 30th September, 2021
11-Oct-21	Change in the Key Managerial Personnel: The resignation ofCS Manisha Chitgopekar from the post of Company Secretary andCompliance Officer of the Company effective from closing of business hours on Monday, 11th October, 2021 and appointment of Mr. Nikhil Deshpande as Company Secretary and Key Managerial Personnel pursuant to the provisions of Section 203 of the Companies Act, 2013 and as Compliance Officer effective from Tuesday, 12th October, 2021, pursuant to the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015
11-Oct-21	Pursuant to the provisions of Regulation 32 (1) of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 30th September, 2021.
11-Oct-21	Press Release - Unaudited Financial Results for the quarter and six months ended on 30th September, 2021.
11-Oct-21	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a Earnings Presentation for on Unaudited Financial Results of the Company for the period ended on 30th September, 2021.
11-Oct-21	The resignation of CS Manisha Chitgopekar from the post of Company Secretary and Compliance Officer of the Company effective from closing of business hours on Monday, 11th October, 2021
11-Oct-21	Appointment of Mr. Nikhil Deshpande as Company Secretary and Key Managerial Personnel pursuant to the provisions of Section 203 of the Companies Act, 2013 and as Compliance Officer effective from Tuesday, 12th October, 2021, pursuant to the provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI (Prohibition of Insider Trading) Regulations, 2015.
13-Oct-21	Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Unaudited Financial Results of the Company for the quarter and six months ended on 30th September, 2021, published in Financial Express (All Editions) and Lokсsatta (Pune Edition), both dated on 13th October, 2021.
19-Oct-21	Please find enclosed the transcript of the Q2 and H1 FY22 Earnings Conference Call conducted on 12th October, 2021, for your information and records.
9-Nov-21	Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions for the half year ended 30th September, 2021.
12-Nov-21	Pursuant to Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have attached herewith, a Report of Monitoring Agency i.e. ICICI Bank Limited for the quarter ended 30th September, 2021.
4-Dec-21	Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"), we would like to inform you that based on CRISIL Rating letter dated 03rd December, 2021, the credit rating of the Company, has been upgraded as per the attached letter.  The detailed report on Credit Rating issued by CRISIL is accessible on the following link:  <a href="https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/KrsnaaDiagnosticsLimited_December%2002,%202021_RR_282773.html">https://www.crisil.com/mnt/winshare/Ratings/RatingList/RatingDocs/KrsnaaDiagnosticsLimited_December%2002,%202021_RR_282773.html</a>
24-Dec-21	Inauguration of Diagnostics Centers under Punjab Radiology and Pathology Project.
3-Jan-22	Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Inauguration Of Diagnostics Centers Under Punjab Radiology and Pathology Project.
5-Jan-22	Pursuant to the provisions of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith the certificates for the quarter ended December 31, 2021, received from KFin Technologies Private Limited (SEBI Registration Number INR000000221), Registrar and Share Transfer Agent of the Company. It is requested to take this intimation on record and acknowledge receipt of the same.
7-Jan-22	Inauguration of Diagnostics Centers under Punjab Radiology and Pathology Project.
11-Jan-22	Statement Of Investor Complaints For The Quarter Ended December 2021
17-Jan-22	Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"), we would like to inform you that ICRA, has assigned a long-term rating of [ICRA]A (pronounced ICRA A) and a short-term rating of [ICRA]A1 (pronounced ICRA A one) for INR 85.00 Crore Line of Credit (LOC) of the Company. The Outlook on the long-term rating is Stable.
22-Jan-22	Inauguration of Diagnostics Center at K. B. Bhabha Hospital, Kuria, Mumbai.
24-Jan-22	Krснаа Diagnostics Lidhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2022, inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of the SEBI (LODR) Regulations, 2015 and all other applicable provisions in this behalf, we wish to inform you that the Meeting of the Board of Directors of Krснаа Diagnostics Limited ("the Company") is scheduled to be held on Monday, 31st January, 2022, through audio-visual means, inter alia, to consider and approve Unaudited (Standalone and Consolidated) Financial Results ("UFR"), for the quarter ended on 31st December, 2021 and to take on record, the Limited Review Report thereon. The Company will hold investor / analyst call post Board Meeting. The details of the said call will be intimated to the stock exchanges separately in due course. It is requested to take the same on your records.

31-Jan-22	Please find enclosed herewith Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter and nine months ended 31st December, 2021 along with Limited Review report thereon
31-Jan-22	Outcome of Board Meeting
31-Jan-22	Pursuant to the provisions of Regulation 32 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 31st December, 2021. Request you to take the same on your records.
31-Jan-22	This has reference to the captioned subject and our earlier communication w.r.t. a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 31st December, 2021. Kindly find attached herewith, a revised / corrected Statement of deviation(s) or variation(s). In the earlier statement of deviation(s) or variation(s) the amount raised was wrongly mentioned as INR 400 Million instead of INR 400 Crores. Kindly take the revised disclosure on your records.
31-Jan-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a Press Release on Unaudited Financial Results of the Company for the quarter and nine months ended on 31 <sup>st</sup> December, 2021. Request you to take the same on your records.
2-Feb-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Unaudited Financial Results of the Company for the quarter and nine months ended on 31st December, 2021, published in Financial Express (All Editions) and Loksatta (Pune Edition), both dated on 02nd February, 2022. Financial Statement for the quarter and nine months ended as mentioned above has also been published on website (www.krsnaadiagnostics.com) of the Company. Request you to take the same on your records.
2-Feb-22	Q3FY2022 Earnings Presentation
8-Feb-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Department of Medical Health & Family Welfare Government of Uttar Pradesh has awarded a Tender for providing CT Scan Services in the 8 District Hospitals in the State of Uttar Pradesh to the Company.
8-Feb-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Health Department, U.T., Chandigarh has awarded a Tender for Development, Operation and Maintenance of Radiology Imaging Diagnostic Centre in The Government Multi Speciality Hospital, Sector - 16, Chandigarh (GMSH-16) on Public Private Partnership (PPP) basis.
9-Feb-22	The transcript of the Q3FY22 Earnings Conference Call conducted on 03rd February, 2022.
11-Jan-22	Inauguration of Diagnostics Center at Bilaspur, Himachal Pradesh.
12-Feb-22	Pursuant to Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have attached herewith, a Report of Monitoring Agency i.e. ICICI Bank Limited for the quarter ended 31st December, 2021. You are requested to take the same on your record
21-Feb-22	Winning of Tender for providing Diagnostic / Laboratory Services in H.P. Govt. Health Institutions in entire State of Himachal Pradesh to the Company.
14-Mar-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that Mr. Shivananda Rao has tendered his resignation from the post of Chief Operating Officer of the Company effective from closing of business hours on Monday, 14th March, 2022.
14-Mar-22	Please find enclosed herewith a press release titled "Krsnaa Diagnostics strengthens its leadership with the appointment of a new Chief Operating Officer", which is being released to Press.
21-Mar-22	Change of Name of Registrar and Share Transfer Agent of the Company from "KFin Technologies Private Limited" to "KFin Technologies Limited".
28-Mar-22	Inauguration of Diagnostics Center at Solan, Himachal Pradesh.
31-Mar-22	Pursuant to the relevant circulars issued by BSE Limited and National Stock Exchange of India Limited, read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, this is to intimate that the trading window for dealing in shares of the Company for all Directors, Key Managerial Personnel, Designated Employees, and other connected persons, will remain closed from 1st April, 2022 till end of two calendar days from the date of submission of financial results of the Company for the quarter and year ending on 31st March, 2022, to the Stock Exchanges, unless decided otherwise. The date of the Board Meeting to consider and approve financial results for the quarter and year ending on 31st March, 2022, will be informed in due course.
5-Apr-22	Statement Of Investor Complaints For The Quarter Ended March 2022
5-Apr-22	Compliance Certificate As Per Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended 31st March, 2022
5-Apr-22	Certificates as per Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2022.
8-Apr-22	As per Regulation 40(10) of SEBI LODR, we are submitting herewith a Certificate dated 07th April, 2022 issued by M/S Dinesh Birla & Associates, Company Secretaries, pertaining to yearly audit conducted by them pursuant to Regulation 40(9) SEBI LODR for the year ended on 31st March, 2022.
27-Apr-22	Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
13-May-22	Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
14-May-22	Monitoring Agency Report for the quarter ended 31st March, 2022 submitted
14-May-22	Statement Of Deviation(S) Or Variation(S) for the quarter ended on 31st March, 2022 submitted
21-May-22	Krsnaa Diagnostics Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022, inter alia, to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) and other applicable provisions, rules, and regulations, if any, this is to inform you that a meeting of Board of Directors (Board) of the Company, is scheduled to be held on Saturday, 28th May, 2022, inter-alia, to consider and approve: 1. Financial Results: a. Audited (Standalone and Consolidated) Financial Results, for the quarter ended on 31st March, 2022, and to take on record, the Auditor's Report thereon; and b. Audited (Standalone and Consolidated) Financial Statements of the Company, for the financial year ended on 31st March, 2022, and to take on record, the Auditor's Report thereon. 2. Proposal for recommendation of Final Dividend, for the Financial Year 2021-22. It is requested to take the same on your records.
24-May-22	Report of Monitoring Agency for the Initial Public Offer- Revised submitted
27-May-22	In compliance with the SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please find enclosed the Annual Secretarial Compliance report for the year ended 31st March, 2022, issued by Dinesh Birla & Associates, Practicing Company Secretary, Secretarial Auditor of the Company. It is requested to take the same on your records.
28-May-22	Outcome of Board Meeting held on 28-May-2022 to consider financial statements for the period ended March 2022. Dividend and change in Board of Directors.
28-May-22	Board of Directors at its meeting held on 28-May-2022, Declared Dividend of Rs. 2.50 per equity share
28-May-22	Change in Board of Directors: 1. Appointment of Director Appointment of Mr. Adesh Kumar Gupta (DIN: 00020403) as Independent Director, on the Board of the Company, for a term of 5 years effective from 28th May, 2022, subject to Member's and other applicable approval(s). Further details pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are enclosed as Annexure A. 2. Mr. Prakash Iyer (DIN: 00529591), has tendered his resignation from the post of Independent Director of the Company w.e.f. close of business hours on 28th May, 2022. The same has been taken on record by the Board of Directors in the Meeting held today. Further details pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, are enclosed as Annexure B.
28-May-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a Press Release on Audited Financial Results of the Company for the quarter and year ended on 31st March, 2022. Request you to take the same on your records.
28-May-22	With reference to captioned subject, please note that the Company had filed the Annual Secretarial Compliance report (the Report) for the year ended 31st March, 2022, issued by Dinesh Birla & Associates, Practicing Company Secretary, Secretarial Auditor of the Company on 27th May, 2022. However, there is a small correction in the Report w.r.t. change of date on for the heading on Page no. 2 wherein the date was inadvertently mentioned as 31st March, 2021 instead of 31st March, 2022. There is no other material change in the Report. It is requested to take the revised file of the Report on your records.
30-May-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Audited Financial Results of the Company for the quarter and year ended on 31st March, 2022, published in Financial Express (All Editions) and Loksatta (Pune Edition), both dated on 30th May, 2022.
31-May-22	This has reference to the captioned subject and our earlier communication dated 28th May, 2022 regarding resignation of Mr. Prakash Iyer (DIN: 00529591) as an Independent Director of the Company effective from close of business hours on 28th May, 2022. We hereby submit additional information w.r.t. resignation of Mr. Iyer pursuant to the provisions of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as Annexure A to this Letter along with a copy of the Resignation Letter in this behalf. It is requested to take this intimation on your records.
31-May-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith an Earnings Presentation on Audited Financial Results of the Company for quarter and year ended on 31st March, 2022. Request you to take the same on your records.
7-Jun-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Company has been awarded contract in the state of Tripura by the Mission Director, National Health Mission, State Health & Family Welfare Society, Tripura for Image Transmission & Reporting of Radiology Images and Selective Radiology Services ("X-ray Tele Radiology Services"). Krsnaa Diagnostics now has its footprint across 15 states with addition of State of Tripura where it will be having presence across all districts. We have enclosed, the disclosure in terms of the SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 as Annexure I to this letter. Request you to take the same on your records.
9-Jun-22	Please find enclosed the transcript of the Q4 and FY22 Earnings Conference Call conducted on 02nd June, 2022. Request you to take the same on your records.
11-Jun-22	Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith disclosures of related party transactions on consolidated basis in the revised format, as prescribed by SEBI Circular No. SEBI/HO/CFD/CMD/ICIR/P/2021/662 dated 22nd November 2021, for the half year ended on 31st March 2022.
16-Jun-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with the Government of Punjab ("Agreement") for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company has operationalized diagnostics centers at three more locations viz. Ludhiana, Jalandhar and Tarn Taran.
24-Jun-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with the Government of Punjab ("Agreement") for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company has operationalized diagnostics center at Khanna, city and Municipal Council in Ludhiana District. Request you to take the same on your records.
5-Jul-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that "The Office of the Medical Director, Indira Gandhi Hospital, Government of NCT of Delhi has awarded a Tender for establishment, operation and management of Radiology Unit (for providing MRI and CT Scan services) in the Department of Radiology in the premises of Indira Gandhi Hospital, Dwarka, Sector- 9, New Delhi -110077 on Public Private Partnership (PPP) basis. Krsnaa Diagnostics now has its footprints in the Capital of India.
5-Jul-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with the Government of Punjab ("Agreement") for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company has operationalized diagnostics center at Moga, Punjab.
6-Jul-22	Statement Of Investor Complaints For The Quarter Ended June 2022
6-Jul-22	Pursuant to the provisions of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith the certificates for the quarter ended 30th June, 2022, received from KFin Technologies Limited (Formerly known as KFin Technologies Private Limited (SEBI Registration Number INR000000221), Registrar and Share Transfer Agent of the Company.
19-Jul-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that "Rajasthan Medical Education Society (Directorate of Medical Education), Government of Rajasthan" has awarded a Tender for Supply, Installation, Operation and Maintenance of CT Scan Center at Raj - MES Medical College located at Churu, a City in Rajasthan on Public Private Partnership (PPP) basis.
21-Jul-22	Reconstitution of Committees of the Board.
25-Jul-22	Krsnaa Diagnostics to add 40 New CT Scan centers after winning Maharashtra and Churu tenders - 40%+ addition to existing CT Scan contracts. Krsnaa has been awarded one of the largest tenders in Public Private Partnerships for providing CT Scan Services by Commissionerate of Health Services, Maharashtra. The contract includes installation and / or operation of 39 CT Scanners across 39 District / Sub district Hospitals in Maharashtra with project value of approximately INR 75 Crore. This will allow Krsnaa Diagnostics to expand its footprint and strengthen its presence in major cities as well as Tier II & Tier III locations across the State of Maharashtra.
26-Jul-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Notice of Postal Ballot as issued to the Members of the Company for seeking their approval by means of Postal Ballot through remote e-voting for the following ordinary resolution: 1. Appointment of Mr. Adesh Kumar Gupta (DIN: 00020403) as an Independent Director The remote e-voting period shall commence from 9.00 am (IST) on Thursday, 28th July, 2022 and end at 5.00 pm (IST) on Friday, 26th August, 2022. The results of the Postal Ballot will be declared on or before Sunday, 28th August, 2022. The above referred notice is also available on the website of the Company viz. <a href="https://krsnaadiagnostics.com">https://krsnaadiagnostics.com</a> . It is requested to take this intimation on record and acknowledge receipt of the same.
27-Jul-22	Postal Ballot Notice and e-voting Information.

27-Jul-22	This has reference to the Postal Ballot Notice dated 21st July, 2022, which has already been emailed to the shareholders of the Company on 26th July, 2022. A Corrigendum is being issued to inform the shareholders of the Company regarding amendments in the Postal Ballot Notice and explanatory statement. A copy of detailed corrigendum is enclosed herewith. Except as detailed in the attached corrigendum, all other terms and contents of the Postal Ballot Notice along with Explanatory Statement dated 21st July, 2022, shall remain unchanged. This corrigendum will also be available on the website of the Company <a href="https://krsnaadiagnostics.com">https://krsnaadiagnostics.com</a> . Please note that on and from the date hereof, the Postal Ballot Notice shall always be read in conjunction with this Corrigendum. Note: The e-voting period shall commence from 9.00 a.m (IST) on Thursday, 28th July, 2022 and end at 5.00 p.m. (IST) on Friday, 26th August, 2022, both days inclusive.
28-Jul-22	Krsnaa Diagnostics Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022, inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of the SEBI (LODR) Regulations, 2015 and all other applicable provisions in this behalf, we wish to inform you that the Meeting of the Board of Directors of Krsnaa Diagnostics Limited ("the Company") is scheduled to be held on Thursday, 04th August, 2022, inter alia, to consider and approve Unaudited (Standalone and Consolidated) Financial Results ("UFR"), for the quarter ended on 30th June, 2022 and to take on record, the Limited Review Report thereon. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, and the underlying Code of the Company, the Trading Window for dealing in securities of the Company, is already closed with effect from 01st July, 2022. The Company will hold investor / analyst call post Board Meeting. The details of the said call will be intimated to the stock exchanges separately in due course. It is requested to take the same on your records
29-Jul-22	Pursuant to the provisions of Regulation 30 and Schedule III, Part A Para B of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in terms of the policy for determination and disclosure of Material Event / Information of the Company, we would like to inform that the Income Tax Department conducted a search under the powers conferred to them by the provisions of the Section 132 of the Income Tax Act, 1961 at the premises of the Company and at other locations. The Company has provided all possible assistance to the officials and furnished all explanations, information and clarifications as desired by them and continue to co-operate with them in this matter. We also wish to thank our employees for their continuous and unconditional support. We wish to inform that the proceedings have absolutely no impact on the operational performance of the Company. This is for your kind information and records please.
1-Aug-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with the Government of Punjab ("Agreement") for procurement, operation and maintenance of 24 new CT Scanners, 6 new MRI Machines, 30 Pathological Laboratories, 1 Referral Laboratory and 95 Collection Centers across the State of Punjab, the Company has operationalized diagnostics center at Three more locations viz. Faridkot, Hoshiarpur and Phagwara.
2-Aug-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a Statement being issued by the Company.
4-Aug-22	Please find enclosed herewith Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended on 30th June, 2022 along with Limited Review report thereon
4-Aug-22	Outcome of Board Meeting
4-Aug-22	Record date Intimation for Payment of final dividend
4-Aug-22	Pursuant to the provisions of Regulation 32 (f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 30th June, 2022.
4-Aug-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith a Press Release on Unaudited Financial Results of the Company for the quarter ended on 30th June, 2022.
4-Aug-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith an Earnings Presentation on Unaudited Financial Results of the Company for the period ended on 30th June, 2022.
6-Aug-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Unaudited Financial Results of the Company for the quarter ended on 30th June, 2022, published in Financial Express (All Editions) and Loksatta (Pune Edition), both dated on 06th August, 2022. Financial Statement for the quarter ended as mentioned above has also been published on website ( <a href="http://www.krsnaadiagnostics.com">www.krsnaadiagnostics.com</a> ) of the Company. Request you to take the same on your records.
12-Aug-22	Monitoring Agency Report for the quarter ended 30th June, 2022.
12-Aug-22	Transcript of the Q1FY23 Earnings Call conducted on 05th August, 2022.
25-Aug-22	Pursuant to the applicable provisions of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, and relevant circular(s) issued by the Ministry of Corporate Affairs (MCA) and SEBI in this regards, please find enclosed herewith copies of newspaper advertisement(s) published in Financial Express (All Editions) and Loksatta (Pune Edition), both dated on 25th August, 2022. Request you to take the same on your records.
27-Aug-22	Outcome / Result of Postal Ballot (E-Voting) Result as per Regulation 44 (3) of SEBI (Listing Obligations and Disclosures Requirement), Regulation 2015.
29-Aug-22	Krsnaa Diagnostics Ltd has informed exchanges regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015.
5-Sep-22	This has reference to our earlier intimation dated 04th August, 2022 regarding 12th Annual General Meeting (AGM) of the Company which is scheduled to be held on Tuesday, 27th September, 2022. We have attached herewith a copy of the Notice of 12th Annual General Meeting (AGM). Request you to take the same on your records.
5-Sep-22	12th Annual Report of Krsnaa Diagnostics Limited for FY2021-22.
6-Sep-22	Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of newspaper advertisement giving details of the completion of electronic dispatch of Annual Report for FY2021-22, Notice of 12th Annual General Meeting to be held via Video Conferencing / Other Audio-Visual Means (VCOAVM), cut-off date and e-voting information published in Financial Express (All Edition) and Loksatta (Pune Edition) both dated on 06th September, 2022.
27-Sep-22	Proceedings, Voting Results and Scrutinizer's Report in respect of the 12th Annual General Meeting of the Company.
28-Sep-22	Intimation of Alteration of Memorandum of Association.
28-Sep-22	Please find enclosed herewith a press release titled "Krsnaa Diagnostics to launch 600 new centers across India, foray into retail healthcare services", which is being released to Press.
30-Sep-22	Commencement Of Operations Of Diagnostics Centers under various Projects
30-Sep-22	Pursuant to the relevant circulars issued by BSE Ltd. and National Stock Exchange of India Ltd., read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, this is to intimate that the trading window for dealing in shares of the Company for all Directors, Key Managerial Personnel, Designated Employees, and other Connected Persons, will remain closed from 01st October, 2022 till end of two calendar days from the date of submission of Unaudited Financial Results of the Company for the quarter and half year ending on 30th September, 2022, to the stock exchanges, unless decided otherwise. The date of the Board Meeting to consider and approve Unaudited Financial Results for the quarter and half year ending on 30th September, 2022, will be informed in due course. Request you to take the same on your records.
7-Oct-22	Statement Of Investor Complaints For The Quarter Ended September 2022 submitted
7-Oct-22	Pursuant to the provisions of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith the certificates for the quarter ended 30th September 2022, received from KFin Technologies Limited (Formerly known as KFin Technologies Private Limited (SEBI Registration Number NR000000221), Registrar and Share Transfer Agent of the Company. It is requested to take this intimation on record and acknowledge receipt of the same.
1-Nov-22	Krsnaa Diagnostics Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022, inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of the SEBI (LODR) Regulations, 2015 and all other applicable provisions in this behalf, we wish to inform you that the Meeting of the Board of Directors of Krsnaa Diagnostics Limited ("the Company") is scheduled to be held on Wednesday, 09th November, 2022, inter alia, to consider and approve Unaudited (Standalone and Consolidated) Financial Results ("UFR"), for the quarter and half year ended on 30th September, 2022 and to take on record, the Limited Review Report thereon. Further, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, and the underlying Code of the Company, the Trading Window for dealing in securities of the Company, is already closed with effect from 01st October, 2022.
9-Nov-22	Please find enclosed herewith Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter and half year ended on 30th September, 2022 along with Limited Review report thereon.
9-Nov-22	This is to inform you that the Board of Directors of the Company at its meeting held today, which commenced at 01:45 p.m. and concluded at 04:57 p.m., inter-alia, unanimously approved/ consented/ took on record the following: Unaudited Results
9-Nov-22	Pursuant to the provisions of Regulation 32 (1) of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 30th September, 2022.
9-Nov-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached here with a Press Release on Unaudited Financial Results of the Company for the period ended on 30th September, 2022.
9-Nov-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith an Earnings Presentation on Unaudited Financial Results of the Company for the period ended on 30th September, 2022.
11-Nov-22	Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith clippings of newspaper publication of the Unaudited Financial Results of the Company for the quarter and half year ended on 30th September, 2022, published in Financial Express (All Editions) and Loksatta (Pune Edition), both dated on 11th November, 2022. Financial Statement for the quarter and half year ended as mentioned above has also been published on website ( <a href="http://www.krsnaadiagnostics.com">www.krsnaadiagnostics.com</a> ) of the Company.
14-Nov-22	Pursuant to Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have attached herewith a Report of Monitoring Agency i.e. ICICI Bank Limited for the quarter ended 30th September, 2022.
17-Nov-22	Please find enclosed the transcript of the Q2H1FY23 Earnings Conference Call conducted on 10th November, 2022.
23-Nov-22	Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith disclosure of related party transactions on consolidated basis for the half year ended on 30th September, 2022.
6-Dec-22	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Company has operationalized 1 Diagnostics Center at Lokbandhu Hospital, Lucknow Uttar Pradesh out of 8 Diagnostics Centers to be established as a part of the Agreement with Department of Medical, Health & Family Welfare, Government of Uttar Pradesh (GOUF).
31-Dec-22	Pursuant to the relevant circulars issued by BSE Ltd. and National Stock Exchange of India Ltd., read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018, this is to intimate that the trading window for dealing in shares of the Company for all Directors, Key Managerial Personnel, Designated Employees, and other Connected Persons, will remain closed from 01st January, 2023 till end of two calendar days from the date of submission of Unaudited Financial Results of the Company for the quarter and nine-months ending on 31st December, 2022, to the stock exchanges, unless decided otherwise. The date of the Board Meeting to consider and approve Unaudited Financial Results for the quarter and nine-months ending on 31st December, 2022, will be informed in due course.



3-Jan-23	Intimation under Regulation 30(6) of SEBI (LODR) Regulations, 2015 - Intimation of Credit Rating.
4-Jan-23	Pursuant to the provisions of Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith the certificates for the quarter ended 31st December, 2022, received from KFin Technologies Limited (Formerly known as KFin Technologies Private Limited (SEBI Registration Number INR000000221), Registrar and Share Transfer Agent of the Company.
18-Jan-23	Commencement of Operations of Diagnostics Centers in the State of Punjab
20-Jan-23	Commencement of Operations of Diagnostics Centers in the State of Himachal Pradesh
24-Jan-23	In terms of earlier intimation about winning of a Tender to develop, operate and maintain Radiology Imaging Diagnostic Center at Government Multi Specialty Hospital, Sector - 16, Chandigarh in the month of February, 2022, the Company has operationalized its Diagnostics Center for providing MRI Services at the allocated place.
28-Jan-23	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Company has operationalized 1 Diagnostics Center at District Hospital - Male Akbarpur, Kanpur Dehat Uttar Pradesh. This is the Second Diagnostics Center operationalized by the Company out of 8 Diagnostics Centers to be established as a part of the Agreement with Department of Medical, Health & Family Welfare, Government of Uttar Pradesh (GOUPI). Request you to take the same on your records.
30-Jan-23	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that Brihanmumbai Municipal Corporation, Mumbai, Maharashtra has awarded a Tender to the Company to provide services of Lab Investigation Facilities under "Hinduhridaysamrat Balasaheb Thakeray Chikitsa" for BMC Dispensaries and Hospitals in Mumbai, Maharashtra on Public Private Partnership (PPP) basis. We have enclosed, the disclosure in terms of the SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 as Annexure I to this letter. Request you to take the same on your records.
3-Feb-23	In terms of earlier intimation about winning of a Tender for providing Image Transmission and Reporting of Radiology Images and Selective Radiology Services (X-ray Tele Radiology Services) across all districts in the State of Tripura during the month of June, 2022, the Company has operationalized its services at all the allocated places as on the date of this disclosure.
3-Feb-23	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that the Dhule Municipal Corporation, Dhule, Maharashtra and the Company has entered in to an agreement for Installation, Operation and Maintenance of Radiology and Pathology Center at Late R. R. Pail Commercial Complex located at Dhule, a City in Maharashtra on Public Private Partnership (PPP) basis.
3-Feb-23	Krснаа Diagnostics Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023, inter alia, to consider and approve Unaudited (Standalone and Consolidated) Financial Results ("UFR"), for the quarter and nine months ended on 31st December, 2022
7-Feb-23	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that Mission Directorate, National Health Mission, Odisha has awarded a Tender to Establish & Operate the Laboratory setup in a Hub & Spoke Model at various Government Health Institutions in Odisha State on Public Private Partnership (PPP) basis.
13-Feb-23	Please find enclosed herewith Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter and nine-months ended on 31st December, 2022 along with Limited Review report thereon.
13-Feb-23	Outcome of Board Meeting held on 13.02.2023 which commenced at 02:00 p.m. and concluded at 04:30 p.m.
13-Feb-23	Pursuant to the provisions of Regulation 32 (1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith a Statement on Deviation(s) or Variation(s) in utilization of funds raised through Initial Public Offer, for the quarter ended on 31st December, 2022.
13-Feb-23	Press Release - Unaudited Financial Results for the period ended on 31st December, 2022
13-Feb-23	Press Release - Unaudited Financial Results for the period ended on 31st December, 2022 - Revised
13-Feb-23	Q3FY2023 Earnings Presentation
14-Feb-23	Pursuant to Regulation 41(4) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have attached herewith a Report of Monitoring Agency i.e. ICICI Bank Limited for the quarter ended 31st December, 2022.
14-Feb-23	Audio Recording of Earnings Conference Call pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
23-Feb-23	Inauguration Of Diagnostics Center Under Uttar Pradesh CT Scan Project.
4-Mar-23	Commencement Of Operations Of Diagnostics Center Under Punjab Radiology And Pathology Project.
23-Mar-23	Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
25-Mar-23	Board Meeting Outcome for Held On 25Th March, 2023 Inter-Alia, Approved The Formation Of Operations Committee (Non Statutory Committee).
10-Apr-23	This has reference to the captioned subject and our earlier communication dated 30th January, 2023 regarding winning of Tender to provide services of Lab Investigation Facilities under "Hinduhridaysamrat Balasaheb Thakeray Chikitsa" for BMC Dispensaries and Hospitals in Mumbai, Maharashtra on Public Private Partnership (PPP) basis. We would like to further inform that, Brihanmumbai Municipal Corporation, Mumbai, Maharashtra has directed us to set up additional 47 Hinduhridaysamrat Balasaheb Thakeray Clinics to provide manpower and logistics facility for blood collection upon same terms and conditions mentioned in the existing Tender awarded to the Company. Request you to take the same on your records.
10-Apr-23	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that Mira-Bhayandar Municipal Corporation, Thane, Maharashtra has awarded a Tender to the Company to provide diagnostics services (Both Radiology and Pathology) to serve the patients falling under the jurisdiction of Mira-Bhayandar Municipal Corporation on Public Private Partnership (PPP) basis.
17-Apr-23	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that Mira-Bhayandar Municipal Corporation, Thane, Maharashtra has awarded a Tender to the Company to provide diagnostics services (Both Radiology and Pathology) to serve the patients falling under the jurisdiction of Mira-Bhayandar Municipal Corporation on Public Private Partnership (PPP) basis.
22-Apr-23	Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
25-Apr-23	Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Para A of Schedule III
28-Apr-23	In line with the disclosure given by the Company dated 25th April, 2023, in the interim, Ms. Pallavi Bhatevara, Managing Director of the Company has been
8-May-23	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that as a part of the Agreement with Department of Medical, Health & Family Welfare, Government of Uttar Pradesh (GOUPI) for providing CT Scan services in the eight District Hospitals in the state of Uttar Pradesh, the Company has Commenced its fourth out of eight Diagnostics Center of the above-mentioned Agreement at Ayodhya.
8-May-23	Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"), this is to inform you that pursuant to Tender No. CPD/DY.CH.ENG./ADVT./03/AE-06 which was awarded by Municipal Corporation of Greater Mumbai (MCGM) to the Company for installation, operation, maintenance and running of MRI and CT Scan Center under Public Private Partnership in Municipal Peripheral Hospitals located in Mumbai, the Company has commenced its CT Scan Services at Municipal General Hospital, Rajawadi, Chhatkopar, Mumbai.
12-May-23	In line with the Intimation given by the Company dated 20th March, 2023 with regards to qualification of Company as a L1 Bidder for tender issued by National Health Mission, Rajasthan for providing "Laboratory Services under Free Diagnostics Initiative on HUB and SPOKE Model under NHM" in the entire State of Rajasthan, this is to inform you that Company in consortium with Telecommunications Consultants India Ltd has accepted the Letter of Award issued by the Authority.
27-May-23	Approval of Audited Financial Results for the quarter and year ended 31st March, 2023
27-May-23	Board has recommended a Dividend of Rs. 2.75/- per Equity Share, subject to approval of Shareholders at the Annual General Meeting of the company.
27-May-23	Statement of Deviation & Variation as required under Regulation 32 for the quarter ended 31.03.2023
27-May-23	Company Update on Related party transactions
19-Jul-23	Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Regarding Cancellation Of Letter Of Acceptance.
21-Jul-23	Appointment of Company Secretary and Compliance Officer
28-Jul-23	Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Update On Assam Tender
3-Aug-23	Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015- Update On Rajasthan Tender
5-Aug-23	Board Meeting Intimation for Disclosure Under Regulation 29 Of SEBI (LODR) Regulations, 2015 Regarding Notice Of The Board Meeting
12-Aug-23	Board Meeting Outcome for Held On August 12, 2023
12-Aug-23	Un-Audited (Standalone And Consolidated) Financial Results Of The Company For The Quarter Ended On June 30, 2023.
12-Aug-23	Regulation 32 (1) - Statement Of Deviation(S) Or Variation(S)
14-Aug-23	Announcement under Regulation 30 (LODR)-Monitoring Agency Report
2-Sep-23	Reg. 34 (1) Annual Report.

2-Sep-23	Notice Of 13Th Annual General Meeting Of Krsnaa Diagnostics Limited.
3-Nov-23	Board Meeting Outcome for Held On November 03, 2023 Inter-Alia Approved The Unaudited (Standalone And Consolidated) Financial Results For The Quarter And Half Year Ended September 30, 2023.
3-Nov-23	Intimation For Nomination Of Nodal Officer Under IEPF.
<b>Notes:</b> The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable. For further updates and information, please refer to the website of the Stock Exchanges i.e. <a href="http://www.bseindia.com">www.bseindia.com</a> and/or <a href="http://www.nseindia.com">www.nseindia.com</a>	

**Disclaimer:**

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by JM Financial Limited ("JM Financial") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012.

This information is gathered, inter-alia, from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with the BSE Limited ("BSE") and/or the National Stock Exchange of India Limited ("NSE" and together with the BSE, the "Stock Exchanges") from time to time, price-volume data available on the website of the Stock Exchanges, other sources as disclosed herein and information / clarifications provided by the Issuer.

Nothing in this information is intended by JM Financial to be construed as legal, regulatory, accounting, tax or other advice. While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.

Notwithstanding the above, JM Financial does not make any express or implied representation or warranty as to the authenticity, accuracy or completeness of the information or data contained herein and shall not be liable in any manner for the same. Neither JM Financial nor any of its affiliates or their directors, officers and employees will be responsible or be liable for any loss or damage including any loss of profits incidental or consequential damage, howsoever arising, suffered or incurred by any person accessing and / or using this information. The person accessing and utilizing the information is accordingly once again advised to independently verify the information and satisfy himself about the adequacy, accuracy and completeness for his specific requirement. JM Financial does not undertake to update the information contained herein except as required by applicable law or regulation.